CoChat

Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double‐blind, randomized, placebo‐controlled trial

Akhondzadeh, Shahin, Milajerdi, Mehdi Rafiee, Amini, Homayoun, Tehrani‐Doost, Mehdi · 2006 · Bipolar Disorders
Cited by 78

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Objective: Allopurinol, a hypouricemic agent, has been shown to present therapeutic effects in mania associated with hyperuricemia. This study assessed the efficacy and safety of risperidone as an adjunctive agent to lithium and haloperidol for the treatment of acute mania in hospitalized bipolar patients. Methods: Eighty‐two patients aged between 18 and 49 were eligible to participate, as they met the DSM‐IV criteria for a current manic episode, on the basis of a clinical interview by two academician psychiatrists. In addition, a score of at least 20 points on the Young Mania Rating Scale was required representing at least a moderate‐to‐severe mania. Forty‐one patients were randomly allocated to lithium (1–1.2 mEq/L) + haloperidol (10 mg/day) + allopurinol (300 mg/day) (group A) or lithium (1–1.2 mEq/L) + haloperidol (10 mg/day) + placebo (group B) for an 8‐week, double‐blind, placebo‐controlled study. Patients were assessed by a third‐year resident of psychiatry at baseline and at 7, 14, 28, 42, and 56 days after the medication started. The mean decrease in the Young Mania Rating Scale score from baseline was used as the main outcome measure of response of mania to treatment. The extrapyramidal symptoms were assessed using the Extrapyramidal Symptoms Rating Scale (ESRS). Side effects were systematically recorded throughout the study and were assessed using a checklist. Results: Young Mania Rating Scale scores improved with allopurinol. The difference between the two protocols was significant as indicated by the effect of the group, the between‐subjects factor (F = 5.22, df = 1, p = 0.008). The mean ESRS scores for the placebo group were higher than the allopurinol group. However, the differences were not significant over the trial. The difference between the two groups in the frequency of side effects was not significant except for agitation that was more often in the placebo group. Conclusions: The efficacy of allopurinol to obtain a greater improvement in patients with mania seems to support the purinergic dysfunction in mania.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1399-5618.2006.00363.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 78

Metadata

Authors
Akhondzadeh, S., Milajerdi, M. R., Amini, H., & Tehrani‐Doost, M.
Venue
Bipolar Disorders
Publisher
Wiley
Published
2006-10
Volume
8
Issue
5p1
Pages
485-489
ISSN
  • 1398-5647 (ISSN-L)
  • 1399-5618
OpenAlex
W2060883428
Cited by
78
References
1
FWCI
1.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double‐blind, randomized, placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/j.1399-5618.2006.00363.x
The paper
Akhondzadeh, S., Milajerdi, M. R., Amini, H., & Tehrani‐Doost, M. (2006). Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double‐blind, randomized, placebo‐controlled trial. Bipolar Disorders. https://doi.org/10.1111/j.1399-5618.2006.00363.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.